AF
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Gut microbiome and intestinal inflammation in preclinical stages of rheumatoid arthritis | RMD open |  | 2024 | 49 | 3 | ||
| Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study) | Annals of the rheumatic diseases | | 2024 | 20 | 3 | ||
| Anti-apolipoprotein A-1 IgG, incident cardiovascular events, and lipid paradox in rheumatoid arthritis | Frontiers in cardiovascular medicine | | 2024 | 36 | 4 | ||
| Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RA | BMJ open | | 2024 | 28 | 4 | ||
| Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studies | Joint bone spine | | 2024 | 19 | 3 | ||
| Brief report: can COVID-19 infection trigger rheumatoid arthritis-associated autoimmunity in individuals at risk for the disease? A nested cohort study | Frontiers in medicine | | 2023 | 24 | 3 | ||
| Longitudinal associations between body mass index and changes in disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab | RMD open | | 2023 | 42 | 5 | ||
| The Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire: predicting clinical arthritis development | Scandinavian journal of rheumatology | | 2023 | 40 | 7 | ||
| A potential role for chlamydial infection in rheumatoid arthritis development | Rheumatology | | 2023 | 27 | 17 | ||
| Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy | Rheumatology | | 2023 | 23 | 5 | ||
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update | Annals of the rheumatic diseases | | 2023 | 87 | 54 | ||
| Characterization of serum biomarkers and antibody responses against Prevotella spp. in preclinical and new-onset phase of rheumatic diseases | Frontiers in cellular and infection microbiology | | 2023 | 46 | 30 | ||
| Brief report : assessment of mucosal barrier integrity using serological biomarkers in preclinical stages of rheumatoid arthritis | Frontiers in immunology | | 2023 | 118 | 44 | ||
| Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registries | Arthritis research & therapy | | 2023 | 25 | 4 | ||
| Impact of SARS-CoV2 infection on anti-apolipoprotein A-1 IgG response in inflammatory rheumatic diseases | Frontiers in immunology | | 2023 | 59 | 24 | ||
| Management of giant-cell arteritis in Switzerland: an online national survey | Swiss medical weekly | | 2023 | 138 | 15 | ||
| Omicron-specific cytotoxic t-cell responses after a third dose of mrna covid-19 vaccine among patients with multiple sclerosis treated with ocrelizumab | JAMA neurology | | 2022 | 157 | 76 | ||
| EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology | Annals of the rheumatic diseases | | 2022 | 137 | 41 | ||
| After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK-pot collaboration of registries | Annals of the rheumatic diseases | | 2022 | 169 | 218 | ||
| Nouveautés en médecine 2021 - Rhumatologie | Revue médicale suisse | | 2022 | 225 | 87 | ||
| Accounting for missing data caused by drug cessation in observational comparative effectiveness research: a simulation study | Annals of the rheumatic diseases | | 2022 | 233 | 82 | ||
| Periodontitis in first degree-relatives of individuals with rheumatoid arthritis: a short narrative review | Frontiers in oral health | | 2022 | 122 | 30 | ||
| Prévention vaccinale chez les patients avec des maladies rhumatismales | Revue médicale suisse | | 2022 | 42 | 6 | ||
| Lower odds of remission among women with rheumatoid arthritis: A cohort study in the Swiss Clinical Quality Management cohort | PloS one | | 2022 | 35 | 5 | ||
| Combining individual patient data from randomized and non-randomized studies to predict real-world effectiveness of interventions | Statistical methods in medical research | | 2022 | 99 | 61 | ||
| Global epidemiology of rheumatoid arthritis | Nature reviews. Rheumatology |  | 2022 | 98 | 1 | ||
| Robust T-Cell Responses in Anti-CD20 Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study | Clinical infectious diseases | | 2022 | 137 | 20 | ||
| Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration | Annals of the rheumatic diseases | | 2022 | 273 | 58 | ||
| Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases | Frontiers in immunology | | 2022 | 128 | 26 | ||
| Interruptions of biological and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis : a descriptive cohort study assessing trends in patient characteristics in Switzerland | BMJ open | | 2022 | 16 | 4 | ||
| Editoria : The interplay between the oral microbiota and rheumatoid arthritis | Frontiers in oral health | | 2022 | 26 | 5 | ||
| Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA on the severity of rheumatoid arthritis | Rheumatology | | 2021 | 303 | 273 | ||
| EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors | Annals of the Rheumatic Diseases | | 2021 | 149 | 630 | ||
| Cohort profile: SCREEN-RA: design, methods and perspectives of a Swiss cohort study of first-degree relatives of patients with rheumatoid arthritis | BMJ Open | | 2021 | 177 | 72 | ||
| Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patients | Rheumatology advances in practice | | 2021 | 108 | 35 | ||
| Comparison of psoriatic arthritis and rheumatoid arthritis patients across body mass index categories in Switzerland | Journal of Clinical Medicine | | 2021 | 141 | 47 | ||
| Identification of biological pathways specific to phases preceding rheumatoid arthritis development through gene expression profiling | International Journal of Immunogenetics | | 2021 | 179 | 0 | ||
| Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology | RMD open | | 2021 | 178 | 87 | ||
| Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort | Annals of the Rheumatic Diseases | | 2021 | 118 | 120 | ||
| Greater trochanteric pain syndrome: predicting who will respond to a local glucocorticoid injection | Scandinavian Journal of Rheumatology | | 2021 | 158 | 0 | ||
| Associations between serum antibodies to periodontal pathogens and preclinical phases of rheumatoid arthritis | Rheumatology | | 2021 | 198 | 0 | ||
| Primary and secondary non-response: in need of operational definitions in observational studies | Annals of the Rheumatic Diseases | | 2021 | 180 | 36 | ||
| Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries | Annals of the Rheumatic Diseases | | 2021 | 151 | 109 | ||
| The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries | Rheumatology | | 2021 | 182 | 0 | ||
| Mazzotti reaction: Ivermectin-associated polyarthritis after delayed scabies treatment. Case report and review of the literature | Thérapie | | 2021 | 1 038 | 1 | ||
| Cognitive-bias modification intervention to improve physical activity in patients following a rehabilitation programme: protocol for the randomised controlled IMPACT trial | BMJ open | | 2021 | 163 | 45 | ||
| Impact of assessing patient-reported outcomes with mobile apps on patient–provider interaction | RMD Open | | 2021 | 155 | 42 | ||
| Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximab | RMD open | | 2021 | 177 | 51 | ||
| Personalized prediction of disease activity in patients with rheumatoid arthritis using an adaptive deep neural network | PLOS ONE | | 2021 | 214 | 87 | ||
| EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis | Annals of the Rheumatic Diseases | | 2021 | 184 | 44 | ||
| Is the prevention of rheumatoid arthritis possible? | Clinical Rheumatology | | 2020 | 122 | 0 | ||
| Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis | Arthritis Research and Therapy | | 2020 | 350 | 84 | ||
| EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases | Annals of the Rheumatic Diseases | | 2020 | 265 | 0 | ||
| Associations between gut microbiota and genetic risk for rheumatoid arthritis in the absence of disease: a cross-sectional study | The Lancet. Rheumatology | | 2020 | 144 | 125 | ||
| smarter medicine: liste Top-5 pour le traitement des rhumatismes | Bulletin des médecins suisses | | 2020 | 65 | 15 | ||
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update | Annals of the Rheumatic Diseases | | 2020 | 266 | 108 | ||
| Measuring ACPA in the general population or primary care: is it useful? | RMD Open | | 2020 | 184 | 93 | ||
| Mini-Review: Human Microbiome and Rheumatic Diseases | Frontiers in cellular and infection microbiology | | 2020 | 136 | 77 | ||
| Preferences for treatments to prevent rheumatoid arthritis in Canada and the influence of shared decision-making | Clinical Rheumatology | | 2020 | 105 | 0 | ||
| Predictive factors of treatment persistence in rheumatoid arthritis | Joint, Bone, Spine | | 2020 | 367 | 444 | ||
| Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland | RMD Open | | 2020 | 129 | 53 | ||
| Discordances between clinical and ultrasound measurements of disease activity among RA patients followed in real life | Joint, Bone, Spine | | 2020 | 310 | 0 | ||
| The role of nutritional factors and intestinal microbiota in rheumatoid arthritis development | Nutrients | | 2020 | 120 | 94 | ||
| Detection of circulating highly expanded T-cell clones in at-risk individuals for rheumatoid arthritis before the clinical onset of the disease | Rheumatology | | 2020 | 247 | 8 | ||
| Periodontal status correlates with anti‐citrullinated protein antibodies in first‐degree relatives of individuals with rheumatoid arthritis | Journal of Clinical Periodontology | | 2019 | 339 | 2 | ||
| Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysis | Clinical and Experimental Rheumatology | | 2019 | 300 | 81 | ||
| Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution | Rheumatology | | 2019 | 298 | 0 | ||
| EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases | RMD Open | | 2019 | 276 | 102 | ||
| Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique? | RMD Open | | 2019 | 274 | 108 | ||
| Menopause and possible effect on association between age and anticyclic citrullinated peptide antibodies in women at risk of rheumatoid arthritis | Journal of Rheumatology | | 2019 | 233 | 0 | ||
| Synovitis in rheumatoid arthritis detected by grey scale ultrasound predicts the development of erosions over the next three years | Rheumatology | | 2019 | 243 | 99 | ||
| Glucocorticoid injections for greater trochanteric pain syndrome: a randomised double-blind placebo-controlled (GLUTEAL) trial | Clinical Rheumatology | | 2019 | 248 | 0 | ||
| The links of hepcidin and erythropoietin in the interplay of inflammation and iron deficiency in a large observational study of rheumatoid arthritis | British Journal of Haematology | | 2019 | 196 | 0 | ||
| Role of reproductive and menopausal factors in functional and structural progression of rheumatoid arthritis: results from the SCQM cohort | Rheumatology | | 2019 | 225 | 0 | ||
| 2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis | Annals of the Rheumatic Diseases | | 2019 | 274 | 180 | ||
| Towards standardized patient reported physical function outcome reporting: linking ten commonly used questionnaires to a common metric | Quality of Life Research | | 2019 | 223 | 96 | ||
| Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries | Annals of the Rheumatic Diseases | | 2019 | 300 | 0 | ||
| Ultrasound is not associated with the presence of systemic autoimmunity or symptoms in individuals at risk for rheumatoid arthritis | RMD Open | | 2019 | 267 | 69 | ||
| Preventing rheumatoid arthritis: preferences for and predicted uptake of preventive treatments among high risk individuals | PLOS ONE | | 2019 | 227 | 108 | ||
| Current status of use of big data and artificial intelligence in RMDs: a systematic literature review informing EULAR recommendations | RMD Open | | 2019 | 256 | 84 | ||
| Prevotella copri in individuals at risk for rheumatoid arthritis | Annals of the Rheumatic Diseases | 2019 | 349 | 0 | |||
| Preferences of Patients and At-risk Individuals for Preventive Approaches to Rheumatoid Arthritis | Clinical Therapeutics | | 2019 | 248 | 1 | ||
| Intestinal dysbiosis in RA development: difficulty of establishing causality. Response to: 'Non-causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study' by Inamo | Annals of the Rheumatic Diseases | | 2019 | 287 | 4 | ||
| Lessons learned from rheumatoid arthritis registries | Joint, Bone, Spine | | 2018 | 388 | 2 | ||
| Initial validation and results of the Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire: a EULAR project | RMD Open | | 2018 | 372 | 144 | ||
| Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider | RMD Open | | 2018 | 244 | 117 | ||
| EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatology | RMD Open | | 2018 | 256 | 134 | ||
| Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort | Journal of Rheumatology | | 2018 | 384 | 1 | ||
| Prediction of Real-World Drug Effectiveness Prelaunch: Case Study in Rheumatoid Arthritis | Medical Decision Making | | 2018 | 387 | 0 | ||
| 2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis | Annals of the Rheumatic Diseases | | 2018 | 362 | 0 | ||
| Microbiotes et rhumatismes inflammatoires | Revue médicale suisse | | 2018 | 435 | 136 | ||
| Chagas disease and systemic autoimmune diseases among Bolivian patients in Switzerland | Memórias do Instituto Oswaldo Cruz | | 2018 | 527 | 164 | ||
| Low Hemoglobin and Radiographic Damage Progression in Early Rheumatoid Arthritis: Secondary Analysis From a Phase III Trial | Arthritis Care and Research | | 2018 | 314 | 1 | ||
| Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis | Arthritis Care and Research | | 2018 | 374 | 361 | ||
| Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis | Rheumatology | | 2017 | 447 | 5 | ||
| Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers | Annals of the Rheumatic Diseases | | 2017 | 428 | 162 | ||
| Value of Biomarkers in the Prevention of Rheumatoid Arthritis | Clinical Pharmacology and Therapeutics | | 2017 | 394 | 0 | ||
| The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis | Clinical Rheumatology | | 2017 | 517 | 3 | ||
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update | Annals of the Rheumatic Diseases | | 2017 | 386 | 2 | ||
| Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM) | Clinical Rheumatology | | 2017 | 344 | 0 | ||
| Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotype | PloS one | | 2017 | 496 | 203 | ||
| Environmental factors and hormones in the development of rheumatoid arthritis | Seminars in Immunopathology | | 2017 | 420 | 0 | ||
| Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA) | Clinical Rheumatology | | 2017 | 429 | 2 | ||
| The role of female hormonal factors in the development of rheumatoid arthritis | Rheumatology | | 2017 | 395 | 0 | ||
| Differential impact of systemic lupus erythematosus and rheumatoid arthritis on health-related quality of life | Quality of life research | | 2017 | 475 | 1 | ||
| New viral outbreaks: time for rheumatologists to get involved? | Rheumatology | | 2017 | 413 | 0 | ||
| Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis | Annals of the rheumatic diseases | | 2016 | 517 | 0 | ||
| The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis | Arthritis & rheumatology | | 2016 | 440 | 0 | ||
| Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative | Annals of the Rheumatic Diseases | | 2016 | 389 | 0 | ||
| Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe : Preliminary Report | The New England journal of medicine | | 2016 | 806 | 228 | ||
| Low pre-treatment B-cell counts are not a risk factor of infection in patients treated with rituximab for autoimmune diseases: An observational study | Joint, Bone, Spine | | 2016 | 476 | 0 | ||
| Preventive Treatments for Rheumatoid Arthritis: Issues Regarding Patient Preferences | Current rheumatology reports | | 2016 | 475 | 1 | ||
| Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis | Arthritis and Rheumatology | | 2016 | 326 | 0 | ||
| Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study | EBioMedicine | | 2016 | 410 | 161 | ||
| Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis | Journal of managed care & specialty pharmacy | | 2015 | 490 | 0 | ||
| Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry | Rheumatology | | 2015 | 447 | 0 | ||
| The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers | Rheumatology | | 2015 | 546 | 254 | ||
| The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial | Lancet. Infectious diseases | | 2015 | 630 | 0 | ||
| The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis | Clinical rheumatology | | 2015 | 486 | 0 | ||
| An Internet-based technique for the identification of persons with symptoms of inflammatory polyarthritis of less than 12 weeks | Clinical rheumatology | | 2015 | 403 | 0 | ||
| Anti-tumor necrosis factor drug survival in axial spondyloarthritis is independent of the classification criteria | Rheumatology international | | 2015 | 536 | 0 | ||
| Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study | Annals of the rheumatic diseases | | 2015 | 587 | 0 | ||
| Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study | Annals of the rheumatic diseases | | 2015 | 489 | 263 | ||
| The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries | RMD open | | 2015 | 425 | 212 | ||
| Inflammatory Articular Disease in Patients with Inflammatory Bowel Disease: Result of the Swiss IBD Cohort Study | Inflammatory bowel diseases | | 2015 | 435 | 0 | ||
| The impact of obesity on the development and progression of rheumatoid arthritis | Annals of the rheumatic diseases | | 2014 | 502 | 0 | ||
| Immune-mediated experimental arthritis in IL-33 deficient mice | Cytokine | | 2014 | 599 | 0 | ||
| Prevention of rheumatic diseases: strategies, caveats, and future directions | Rheumatic diseases clinics of North America | 2014 | 439 | 0 | |||
| Adipokines correlate with pain in lower limb osteoarthritis: different associations in hip and knee | International orthopaedics | | 2014 | 531 | 0 | ||
| Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK | PharmacoEconomics | | 2014 | 456 | 447 | ||
| Joint damage progression in patients with rheumatoid arthritis in clinical remission. Do biologics perform better than synthetic antirheumatic drugs? | Journal of rheumatology | | 2014 | 460 | 0 | ||
| Facteurs de risque pour le développement d'une polyarthrite rhumatoïde | Revue médicale suisse | | 2014 | 465 | 2 | ||
| Anaemia may add information to standardised disease activity assessment to predict radiographic damage in rheumatoid arthritis: a prospective cohort study | Annals of the rheumatic diseases | | 2014 | 573 | 559 | ||
| Persistence of ultrasound synovitis in patients with rheumatoid arthritis fulfilling the DAS28 and/or the new ACR/EULAR RA remission definitions: results of an observational cohort study | Joint bone spine | | 2014 | 537 | 0 | ||
| Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial | Arthritis research & therapy | | 2014 | 604 | 164 | ||
| Complications cardio-vasculaires dans les maladies auto-immunes | Revue médicale suisse | | 2013 | 473 | 1 | ||
| Disease activity in rheumatoid arthritis patients at initiation of biologic agents and 1 year of treatment: results from the Swiss SCQM registry | Joint bone spine | | 2013 | 506 | 0 | ||
| Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency | Arthritis research & therapy | | 2013 | 585 | 234 |